| NCT ID | NCT07101250 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Prisma Health-Upstate |
| Condition | Post Operative Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2025-10-30 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized study looks at whether giving patients a medicine called acetazolamide (also called Diamox) before they have laparoscopic hysterectomy may decrease postoperative pain. Researchers will compare acetazolamide to a placebo or inactive drug, to see if acetazolamide helps the pain that may occur after surgery from the gas used in the abdomen during the laparoscopic procedure. Patients will be asked to rate their pain before surgery and after surgery through 24 hours.
Eligibility Criteria
Inclusion Criteria: * Women * Ages 21-65 * undergoing total laparoscopic hysterectomy (TLH) for benign indications with or without bilateral salpingoophorectomy * undergoing total laparoscopic hysterectomy (TLH) for benign indications with or without cystoscopy Exclusion Criteria: * Allergy to acetazolamide or sulfonamides * Known electrolyte disturbances * Pregnancy * Kidney failure or creatinine \>1.5 * Diuretic or lithium use * Chronic obstructive pulmonary disease (COPD) or other lung disease * Central nervous system disorders * Liver disease * Glaucoma * Preoperative or chronic opioid use * Diagnosis of fibromyalgia * Preoperative shoulder pain * Conversion to laparotomy * Intraoperative bladder or bowel injury * Inability to understand or utilize visual analog scale * Undergoing concurrent reconstructive procedures
Contact & Investigator
Paul Miller, JDMD
STUDY CHAIR
Prisma Health
Frequently Asked Questions
Who can join the NCT07101250 clinical trial?
This trial is open to female participants only, aged 21 Years or older, up to 65 Years, studying Post Operative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07101250 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07101250 currently recruiting?
Yes, NCT07101250 is actively recruiting participants. Contact the research team at patti.parker@prismahealth.org for enrollment information.
Where is the NCT07101250 trial being conducted?
This trial is being conducted at Greenville, United States.
Who is sponsoring the NCT07101250 clinical trial?
NCT07101250 is sponsored by Prisma Health-Upstate. The principal investigator is Paul Miller, JDMD at Prisma Health. The trial plans to enroll 100 participants.